LPCN - Lipocine Inc Stock Price, Fair Value and News

$3.080.00 (0.00%)

Delayed as of 23 Apr 2025, 09:39 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

LPCN Price Action

Last 7 days

1.0%

Last 30 days

-13.0%

Last 90 days

-29.8%

Trailing 12 Months

-39.2%

LPCN RSI Chart

LPCN Valuation

Market Cap

16.5M

Price/Earnings (Trailing)

2.0K

Price/Sales (Trailing)

1.47

EV/EBITDA

204.89

Price/Free Cashflow

-12.57

LPCN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

LPCN Fundamentals

LPCN Revenue

Revenue (TTM)

11.2M

Rev. Growth (Yr)

52.87%

Rev. Growth (Qtr)

-23.56%

LPCN Earnings

Earnings (TTM)

8.4K

Earnings Growth (Yr)

178.09%

Earnings Growth (Qtr)

180.32%

LPCN Profitability

EBT Margin

0.08%

Return on Equity

0.04%

Return on Assets

0.04%

Free Cashflow Yield

-7.96%

LPCN Investor Care

Shares Dilution (1Y)

0.65%

Diluted EPS (TTM)

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	5.0M	7.1M	9.1M	11.2M
2023	1.3M	2.1M	0	3.0M
2022	0	10.9M	5.7M	500.0K
2021	0	0	8.2M	16.1M
2019	0	0	165.0K	165.0K
2018	4.1M	428.0K	428.0K	428.0K
2012	0	4.6M	6.2M	7.7M
2011	0	0	0	3.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Lipocine Inc

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

CEO	Dr. Mahesh V. Patel Ph.D.
WEBSITE	lipocine.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	15

Lipocine Inc Frequently Asked Questions

What is the ticker symbol for Lipocine Inc? What does LPCN stand for in stocks?

LPCN is the stock ticker symbol of Lipocine Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lipocine Inc (LPCN)?

As of Tue Apr 22 2025, market cap of Lipocine Inc is 16.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LPCN stock?

You can check LPCN's fair value in chart for subscribers.

Is Lipocine Inc a good stock to buy?

The fair value guage provides a quick view whether LPCN is over valued or under valued. Whether Lipocine Inc is cheap or expensive depends on the assumptions which impact Lipocine Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LPCN.

What is Lipocine Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 22 2025, LPCN's PE ratio (Price to Earnings) is 1.97 Thousand and Price to Sales (PS) ratio is 1.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LPCN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Lipocine Inc's stock?

In the past 10 years, Lipocine Inc has provided -0.305 (multiply by 100 for percentage) rate of return.